Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential gemcitabine + cisplatin followed by carboplatin + paclitaxel in advanced ovarian cancer with suboptimal cytoreduction
2004-002473-23Phase 2Completed
- Sponsor
- Dr. Amalia Velasco
- Start
- Nov 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin, carboplatin and paclitaxel in ovarian cancer and primary peritoneal cancer (PPC), sponsored by Dr. Amalia Velasco. Primary endpoints: Complete clinical response rate and Toxicity. Started Nov 2005; status: completed.
02
Drugs
gemcitabinecisplatincarboplatinpaclitaxel
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2004-002473-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002473-23.